The transcation aims to simplify targeted resequencing workflows by developing automated methods for sequencing library preparation and enrichment of target regions, quantification and quality control.
The automated methods will enable biomedical researchers worldwide to analyze large cohorts to discover and confirm genetic variants that contribute to human disease.
Roche NimbleGen CEO Frank Pitzer said by combining their solutions with Caliper’s NGS workstation, the bottlenecks are eliminated which creates the capacity to analyze large cohorts and optimize research efforts.
Caliper Life Sciences president and CEO Kevin Hrusovsky said its Sciclone NGS Workstation accelerates sequencing sample preparation and enrichment for numerous sequencing chemistries and workflows.
"Together Caliper and Roche NimbleGen are developing targeted sequencing applications that enable studies that analyze variants across large populations to detect and better understand the causal agents of disease," Hrusovsky said.